ELMD Electromed (ELMD) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001488917
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
76
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $421.0K priced
What the filings say about ELMD
Insiders, 180 days
-$2.2M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Electromed insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Electromed, Inc. insiders sold a net $2.2M of stock across 48 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 1, 2024.
- +20.9% median (+20.9% mean) 90-day return after 2 previous buys.
- The trade is 4.7% of the 150,448 shares held after it.
- 2 other insiders sold within 30 days.
- 76 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Cunniff James L. sold about $253.9K of ELMD on Jun 8, 2026; 2 other insiders sold within 30 days and 76 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 1, 2024.
- +20.9% median (+20.9% mean) 90-day return after 2 previous buys.
- The trade is 1.1% of the 148,777 shares held after it.
- 2 other insiders sold within 30 days.
- 76 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Cunniff James L. sold about $61.5K of ELMD on Jun 8, 2026; 2 other insiders sold within 30 days and 76 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 1, 2024.
- +20.9% median (+20.9% mean) 90-day return after 2 previous buys.
- The trade is 0.7% of the 147,751 shares held after it.
- 2 other insiders sold within 30 days.
- 76 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Cunniff James L. sold about $38.8K of ELMD on Jun 8, 2026; 2 other insiders sold within 30 days and 76 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.9% of the 19,638 shares held after it.
- 2 other insiders sold within 30 days.
- 76 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Nagel Bradley M. sold about $6.7K of ELMD on Jun 4, 2026; 2 other insiders sold within 30 days and 76 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 58.6% of the 19,819 shares held after it.
- 2 other insiders sold within 30 days.
- 76 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Nagel Bradley M. sold about $422.3K of ELMD on Jun 4, 2026; 2 other insiders sold within 30 days and 76 funds added in the latest 13F quarter.48 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.2M over 180 days
below 70% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
76 funds bought in last quarter
more than 56% of Medical Devices
Revenue
+15.3% year over year
more than 60% of Medical Devices
Margin
15.3% net margin
more than 88% of Medical Devices
Buybacks
$3.9M repurchased, FY to 2026-06-30
below 76% of Medical Devices
Short interest
2.8% of the float short (float per yahoo 2026-10-27) · 2.6 days to cover · settled 2026-10-15
below 59% of Medical Devices
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 9 in the prior 90
Why it matters
The absence is the signal: 9 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch ELMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+7.8%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ELMD: institutional holders (13F)
13F holdings, latest reported quarter
483,822 sh
$20.5M
465,619 sh
$19.7M
283,232 sh
$12.0M
$9.2M
217,115 sh
$9.2M
Congress trades in ELMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ELMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ELMD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$1.7M position · as of 2026-06-30
1.7%
Gabelli Global Mini Mites Fund
$346.9K position · as of 2026-06-30
1.3%
North Star Micro Cap Fund
$1.3M position · as of 2026-05-31
0.7%
ACUITAS US MICROCAP FUND
$735.0K position · as of 2026-06-30
0.6%
Ultra-Small Company Market Fund
$668.3K position · as of 2026-06-30
0.5%
Hartford Multifactor Small Cap ETF
$269.0K position · as of 2026-07-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · James L. Cunniff
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.8M
$4.3M
$836.2K
+295%
n/a
2024
$1.5M
$4.9M
$756.7K
+105%
n/a
2023
$3.0M
$4.4M
$552.9K
+40%
n/a
2022
$1.1M
$858.0K
$394.3K
+11%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.2M sold by insiders over 180 days, 76 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ELMD financials
Revenue growth
+15.3%
XBRL, annual
Net margin
15.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$73.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ELMD
| FY Jun 2026 | $73.8M |
| FY Jun 2025 | $64.0M |
| FY Jun 2024 | $54.7M |
| FY Jun 2023 | $48.1M |
| FY Jun 2022 | $41.7M |
| Jun 2026 | $19.4M |
| Mar 2026 | $18.6M |
| Dec 2025 | $18.9M |
| Sep 2025 | $16.9M |
| Jun 2025 | $17.4M |
| Mar 2025 | $15.7M |
| Dec 2024 | $16.3M |
| Sep 2024 | $14.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+15.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ELMD
| FY Jun 2026 | +15.3% |
| FY Jun 2025 | +11.8% |
| FY Jun 2024 | +9.4% |
| FY Jun 2023 | +6.6% |
| FY Jun 2022 | +5.5% |
| Jun 2026 | +17.5% |
| Mar 2026 | +16.2% |
| Dec 2025 | +14.6% |
| Sep 2025 | +12.6% |
| Jun 2025 | +12.7% |
| Mar 2025 | +12.1% |
| Dec 2024 | +12.1% |
| Sep 2024 | +10.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$8.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ELMD
| FY Jun 2026 | $8.4M |
| FY Jun 2025 | $11.1M |
| FY Jun 2024 | $8.8M |
| FY Jun 2023 | -$333.0K |
| FY Jun 2022 | -$2.1M |
| Jun 2026 | $2.8M |
| Mar 2026 | $3.3M |
| Dec 2025 | $2.4M |
| Sep 2025 | -$83.0K |
| Jun 2025 | $3.7M |
| Mar 2025 | $2.2M |
| Dec 2024 | $2.9M |
| Sep 2024 | $2.3M |
At each fiscal year end
Single quarter
Debt to equity
0.02x
long-term 2017-09-30 (106 months older than the period end) plus current 2021-12-31 (54 months older than the period end); equity 2026-06-30
Debt to equity ELMD
| FY Jun 2026 | 0.02x |
| FY Jun 2025 | 0.03x |
| FY Jun 2024 | 0.03x |
| FY Jun 2023 | 0.03x |
| FY Jun 2022 | 0.03x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.02x |
| Dec 2025 | 0.03x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
8.51x
TTM operating cash flow over long-term 2017-09-30 (106 months older than the period end) plus current 2021-12-31 (54 months older than the period end)
Cash flow to debt ELMD
| FY Jun 2026 | 8.51x |
| FY Jun 2025 | 10.03x |
| FY Jun 2024 | 7.98x |
| FY Jun 2023 | 1.16x |
| FY Jun 2022 | -0.60x |
| Jun 2026 | 8.51x |
| Mar 2026 | 9.27x |
| Dec 2025 | 8.03x |
| Sep 2025 | 8.14x |
| Jun 2025 | 10.03x |
| Mar 2025 | 10.58x |
| Dec 2024 | 9.95x |
| Sep 2024 | 10.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+23.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ELMD
| FY Jun 2026 | +23.3% |
| FY Jun 2025 | +17.2% |
| FY Jun 2024 | +12.5% |
| FY Jun 2023 | +8.8% |
| FY Jun 2022 | +6.9% |
| Jun 2026 | +23.3% |
| Mar 2026 | +21.7% |
| Dec 2025 | +20.2% |
| Sep 2025 | +19.0% |
| Jun 2025 | +17.2% |
| Mar 2025 | +16.6% |
| Dec 2024 | +16.1% |
| Sep 2024 | +16.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+18.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ELMD
| FY Jun 2026 | +18.8% |
| FY Jun 2025 | +14.2% |
| FY Jun 2024 | +10.5% |
| FY Jun 2023 | +7.3% |
| FY Jun 2022 | +5.9% |
| Jun 2026 | +18.8% |
| Mar 2026 | +18.1% |
| Dec 2025 | +16.8% |
| Sep 2025 | +16.0% |
| Jun 2025 | +14.2% |
| Mar 2025 | +14.1% |
| Dec 2024 | +13.6% |
| Sep 2024 | +13.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+34.3%
operating income after a 21.3% effective tax rate, over long-term 2017-09-30 (106 months older than the period end) plus current 2021-12-31 (54 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ELMD
| FY Jun 2026 | +34.3% |
| FY Jun 2025 | +24.1% |
| FY Jun 2024 | +15.8% |
| FY Jun 2023 | +10.6% |
| FY Jun 2022 | +9.4% |
| Jun 2026 | +34.3% |
| Mar 2026 | +30.9% |
| Dec 2025 | +28.1% |
| Sep 2025 | +25.7% |
| Jun 2025 | +24.1% |
| Mar 2025 | +21.6% |
| Dec 2024 | +21.2% |
| Sep 2024 | +19.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+28.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ELMD
| FY Jun 2026 | +28.5% |
| FY Jun 2025 | +22.0% |
| FY Jun 2024 | +16.0% |
| FY Jun 2023 | +11.1% |
| FY Jun 2022 | +8.9% |
| Jun 2026 | +28.5% |
| Mar 2026 | +28.1% |
| Dec 2025 | +25.7% |
| Sep 2025 | +24.1% |
| Jun 2025 | +22.0% |
| Mar 2025 | +20.7% |
| Dec 2024 | +20.6% |
| Sep 2024 | +21.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
20.32x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ELMD
| FY Jun 2026 | 32.29x |
| FY Jun 2025 | 25.87x |
| FY Jun 2024 | 25.91x |
| FY Jun 2023 | 30.60x |
| FY Jun 2022 | 37.08x |
| Jun 2026 | 32.29x |
| Mar 2026 | 19.84x |
| Dec 2025 | 28.00x |
| Sep 2025 | 26.12x |
| Jun 2025 | 25.87x |
| Mar 2025 | 30.20x |
| Dec 2024 | 39.40x |
| Sep 2024 | 29.82x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$203.4M
market value at close 2026-10-26 on 2026-08-19 shares, plus long-term 2017-09-30 (106 months older than the period end) plus current 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
Enterprise value ELMD
| FY Jun 2026 | $330.9M |
| FY Jun 2025 | $170.3M |
| FY Jun 2024 | $115.2M |
| FY Jun 2023 | $85.5M |
| FY Jun 2022 | $75.0M |
| Jun 2026 | $330.9M |
| Mar 2026 | $177.9M |
| Dec 2025 | $230.2M |
| Sep 2025 | $192.0M |
| Jun 2025 | $170.3M |
| Mar 2025 | $190.1M |
| Dec 2024 | $234.8M |
| Sep 2024 | $172.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield ELMD
| FY Jun 2026 | +2.4% |
| FY Jun 2025 | +6.0% |
| FY Jun 2024 | +6.7% |
| FY Jun 2023 | -0.4% |
| FY Jun 2022 | -2.6% |
| Jun 2026 | +2.4% |
| Mar 2026 | +4.8% |
| Dec 2025 | +3.4% |
| Sep 2025 | +4.3% |
| Jun 2025 | +6.0% |
| Mar 2025 | +5.8% |
| Dec 2024 | +4.4% |
| Sep 2024 | +6.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.38x
P/E over trailing EPS growth of 54%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ELMD
| FY Jun 2026 | 0.60x |
| FY Jun 2025 | 0.56x |
| FY Jun 2024 | 0.39x |
| FY Jun 2023 | 0.88x |
| FY Jun 2022 | n/a |
| Jun 2026 | 0.60x |
| Mar 2026 | 0.40x |
| Dec 2025 | 0.72x |
| Sep 2025 | 0.85x |
| Jun 2025 | 0.56x |
| Mar 2025 | 0.49x |
| Dec 2024 | 0.56x |
| Sep 2024 | 0.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-06 | 2025-06 | 2024-06 | 2023-06 | |
|---|---|---|---|---|
| Revenue | $73.8M | $64.0M | $54.7M | $48.1M |
| Gross profit | $57.9M | $50.0M | $41.7M | $36.5M |
| Operating income | $13.9M | $9.7M | $6.6M | $4.0M |
| Net income | $11.3M | $7.5M | $5.2M | $3.2M |
| EPS (diluted) | 1.30 | 0.85 | 0.58 | 0.36 |
| Operating cash flow | $9.7M | $11.4M | $9.1M | $1.3M |
| Cash | $20.4M | $15.3M | $16.1M | $7.4M |
| Buybacks | $3.9M | $10.0M | $275.0K | $153.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
ELMD Stock Sonar score 6/7 axes
Find similar shapesCompareELMD ranks highest on profitability (96th percentile) and financial health (91st), and lowest on insider conviction (14th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ELMD filings, in plain words
Are Electromed insiders buying or selling ELMD?
In the 180 days to 2026-10-28, Electromed insiders were net sellers, a net $2.2M across purchases and sales reported on Form 4, by 3 sellers.
Read the full summary
In the 180 days to 2026-10-28, Electromed insiders were net sellers of ELMD, a net $2.2M across purchases and sales reported on Form 4 by 3 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
